A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles

British Journal of Clinical Pharmacology

Volumn 42, Issue 2, 1996, Pages 179-186

  Lewis, Lionel D ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Consecutive cycles; Fractionated ifosfamide; Pharmacokinetics

Indexed keywords

IFOSFAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MALE; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0030055579     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03956.x     Document Type: Article

References (34)

1. Sutton GP, Blessing JA, Photopulos G, Berman ML, Homesley HD. Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. Cancer Chemother Pharmacol 1990; 26: S55-58.
2. Zalupski M, Baker LH. Ifosfamide. J Natl Cancer Inst 1988; 80: 556-566.
3. Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its anti-neoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 1991; 42: 428-467.
4. Brock N. Contribution to the pharmacology of ifosfamide. Proceedings of International Holoxan Symposium. 1977. Asia Werke: 15-19.
5. Morgan LR, Harrison EF, Hawke JE, et al. Toxicity of single versus fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study. Semin Oncol 1982; 9: 66-70.
6. Costanzi JJ, Gagliano R, Loukas D, Panettiere FJ, Hokanson JA. Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules. Cancer 1978; 41: 1715-1719.
7. Klein HO, Wickramanayake PD, Christian E, Coerper C. Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557). Cancer 1984; 54: 1193-1203.
8. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 2391-2395.
9. Walker D, Finois JP, Monkman SC, et al. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 1994; 47: 1157-1163.
10. Creaven PJ, Allen LM, Cohen MH. Nelson RL. Studies on the clinical pharmacology and toxicology of isophosphamide (NSC-109724). Cancer Treat Rep 1976; 60: 445-449.
11. Allen LM, Creaven PJ. Activation of the antineoplastic drug isophosphamide by rat liver microsomes. J Pharm Pharmacol 1972; 24: 585-586.
12. Allen LM, Creaven PJ. In vitro liver activation of isophosphamide (NSC 109724). A new oxazaphosphorine. Cancer Chemother Rep 1972; 56: 603-610.
13. Sladek NE. Metabolism of oxazaphosphorines. Pharmacol Ther 1988; 37: 301-355.
14. Low JE, Borch RF, Sladek NE. Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers. Cancer Res 1983; 43: 5815-5820.
15. Brock N, Hoeffer Janker H, Hohorst HJ, Scheef W, Schneider B, Wolf HC. Activation of ifosfamide in man and animals. Arzneimittelforschung 1973; 23: 1-14.
16. Norpoth K. Studies on the metabolism of isophosphamide (NSC-109724) in man. Cancer Treat Rep 1976; 60: 437-443.
17. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029-1036.
18. Lind MJ, Margison JM, Cerny T.Thatcher N, Wilkinson P. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 1989; 49: 753-757.
19. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 1990; 30: 725-732.
20. Lind MJ, Roberts HL, Thatcher N, Idle JR. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother Pharmacol 1990; 26: 105-111.
21. Cerny T, Margison JM, Thatcher N, Wilkinson PM. Bioavailability of ifosfamide in patients with bronchial carcinoma. Cancer Chemother Pharmacol 1986; 18: 261-264.
22. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR. Comparison of continuous infusion and bolus administration of Ifosfamide in children. Eur J Cancer 1995; 31A: 785-790.
23. D'Incalci M, Bolis G, Facchinetti T, et al. Decreased half-life of cyclophosphamide in patients under continual treatment. Eur J Cancer 1979: 15: 7-10.
24. Mouridsen HT, Faber O, Skovsted L. The metabolism of cyclophophamide. Dose dependency and the effect of long term treatment with cyclophosphamide. Cancer 1976; 37: 665-670.
25. Juma F, Rogers HJ, Trounce JR, Bradbrook IA. Pharmacokinetics of intravenous cyclophosphamide in man estimated by gas liquid chromatography. Cancer Chemother Pharmacol 1978; 1: 229-231.
26. Nelson RL, Allen LM, Creaven PJ. Pharmacokinetics of divided-dose ifosfamide. Clin Pharmacol Ther 1975; 19: 365-370.
27. Williams SJ, Baird -Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 1978; ii: 939-941.
28. Chen YL, Le Vraux V, Leneveu A, et al. Acute phase response, interleukin -6, and alteration of cyclosporine Pharmacokinetics. Clin Pharmacol Ther 1994; 55: 649-660.
29. Piazza E, Cattaneo MT, Varini M. Pharmacokinetic studies in lung cancer patients. Cancer 1984; 54: 1187-1192.
30. Ohnaus EE, Breckenridge AM, Park BK. Urinary excretion of 6β-hydroxycortisol and the time course of enzyme induction in man. Eur J Clin Pharmacol 1989; 36: 39-46.
31. Levy RH, Lai AA, Dumain MS. Time dependent kinetics IV: Pharmacokinetic theory of enzyme induction. J Pharm Sci 1979; 68: 398-399.
32. Goss JE, Dickhaus DW. Increased bishydroxycoumarin requirements in patients receiving phenobarbital. N Engl J Med 1965; 273: 1094-1095.
33. Kurowski V, Wagner T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde and 2- and 3-dechloroethylifosfamide in patients on fractionated ifosfamide. Cancer Chemother Pharmacol 1993; 33: 36-42.
34. Boddy AV, Cole M, Pearson ADJ, Idle JR. The kinetics of autoinduction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995; 36: 53-60.